Hannah M. Brooks and Michael T. Hawkes* Pages 62-72 (11)
Methods: Here we provide a narrative review of the literature of peer-reviewed research relating to adjunctive therapies for CM. We discuss regulatory pathways of the NVU, with a focus on the potential for pharmacologic modulation of the NVU to improve CM outcomes.
Results: Recently licensed pharmaceuticals, developed as therapies for cancer or neurologic disease, could be re-purposed for use as host-directed therapies in CM to target pathways involved in endothelial stability and activation.
Conclusion: The findings of this review highlight recently licensed pharmaceuticals that may be developed as future adjunctive therapies for CM.
Cerebral malaria, infectious disease, childhood morbidity, adjunctive therapies, neuroprotective, cerebral edema, endothelial cells.
Department of Pediatrics, University of Alberta, Edmonton, Alberta, Department of Pediatrics, University of Alberta, Edmonton, Alberta